双醋瑞因对骨关节炎患者血清白细胞介素1、肿瘤坏死因子α的影响和临床疗效

Influence and clinical effect of interleukin 1, tumor necrosis factor α in osteoarthritis with Diacerein

目的研究双醋瑞因在骨性关节炎治疗中的应用效果及对白细胞介素1(IL-1)、肿瘤坏死因子α(TNF-α)水平的影响。方法将80例骨关节炎患者随机分为两组,对照组给予美洛昔康15 mg/d,研究组给予双醋瑞因50 mg/d。30 d为1个疗程,共3个疗程。观察两组治疗结束后血清IL-1、TNF-α水平,分析临床疗效。结果治疗后研究组血清IL-1[(12.37±3.22)ng/L]、TNF-α[(16.42±5.56)ng/L]下降明显,与对照组比较差异有统计学意义(P<0.05)。研究组20 m步行痛VAS评分[(3.25±1.32)分]下降,WOMAC骨关节炎评分[(8.75±1.42)分]、AKS膝关节评分[(86.53±9.25)分]及功能评分[(79.31±8.36)分]升高,与对照组比较差异均有统计学意义(均P<0.05)。结论双醋瑞因通过下调血清IL-1、TNF-α水平来改善骨关节炎的治疗效果。

Objective To study interleukin 1 （IL-I）, tumor necrosis factor α （TNF-α） level and cure effect in os- teoarthritis with Diacerein. Methods 80 patients with osteoarthritis were randomly divided into two groups, control group were taken Meloxicara Tablets 15 mg/d, research group were taken Diacerein Capsule for 50 mg/d. 30 d for a period of treatment, a total of 3 period of treatment. After treatment, level of serum IL-1, TNF-a were detected and clinical curative effect was analyzed in two groups. Results After treatment, compared with control group, level of serum IL-1 [（12.37±3.22） ng/L], TNF-α [（16.42±5.56） ng/L] were decreased significantly in research group （P 〈 0.05）. After treatment, compared with control group, 20 m walk pain VAS scores [（3.25±1.32） points] were decreased, the WOMAC osteoarthritis scores [（8.75±1.42） points], AKS knee rating scores [（86.53±9.25） points] and function scores [（79.31±8.36） points] increased （P 〈 0.05）. Conclusion Diacerein improve the treatment effect of osteoarthritis by reduc- ing level of serum IL-1, TNF-α.